Skip to content
by Legal Desire
23 May 2024

Latham & Watkins Advises Sanofi on Co-Exclusive Licensing Agreement With Novavax

Advising firms

Deal team

16 lawyers named
LawyerFirmSeniorityPracticeOffice
Aaron Gardner Lead Latham & Watkins LLP Partner healthcare and life sciences New York
Robert Yeh Latham & Watkins LLP Associate healthcare and life sciences Not stated
Nathan Ajiashvili Latham & Watkins LLP Partner Not stated New York
Kaj Nielson Latham & Watkins LLP Associate Not stated Not stated
Sheen Moaleman Latham & Watkins LLP Associate Not stated Not stated
Andrew Clark Latham & Watkins LLP Partner Not stated Century City
Darryl Steensma Latham & Watkins LLP Counsel Not stated Not stated
Brianna Dollinger Latham & Watkins LLP Associate Not stated Not stated
Michael Sweeney Latham & Watkins LLP Associate Not stated Not stated
Drew O'Sullivan Latham & Watkins LLP Associate Not stated Not stated
Mark Goshgarian Latham & Watkins LLP Associate Not stated Not stated
Gary Mo Latham & Watkins LLP Associate Not stated Not stated
Diana Chung Latham & Watkins LLP Associate Not stated Not stated
Enrique Covarrubias Latham & Watkins LLP Associate Not stated Not stated
Aldrich Huang Latham & Watkins LLP Associate Not stated Not stated
Patrick Chew Latham & Watkins LLP Associate Not stated Not stated

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
SanofiBuy-side
Counterparties
Novavax (Sell-side)